Asset Details
Do you wish to reserve the book?
Comparing the efficacy and safety of safinamide with rasagiline in China Parkinson’s disease patients with a matching adjusted indirect comparison
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Comparing the efficacy and safety of safinamide with rasagiline in China Parkinson’s disease patients with a matching adjusted indirect comparison
Do you wish to request the book?
Comparing the efficacy and safety of safinamide with rasagiline in China Parkinson’s disease patients with a matching adjusted indirect comparison
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Comparing the efficacy and safety of safinamide with rasagiline in China Parkinson’s disease patients with a matching adjusted indirect comparison
2025
Overview
Safinamide and rasagiline are adjuncts to levodopa for the motor fluctuations of Parkinson’s Disease (PD). However, there remains a scarcity of head-to-head studies that directly compare safinamide and rasagiline. This study compared safinamide and rasagiline as adjuncts to levodopa in Chinese PD patients with motor fluctuations by matching-adjusted indirect comparison. Baseline age, sex, BMI, and OFF time were adjusted for matching. Efficacy outcomes were the mean changes in total daily OFF time, UPDRS III, and PDQ-39 from baseline to week 16, which calculated by a weighted covariance model. Safety outcomes included rates of AEs, SAEs, and DCAEs. Bucher method was used for mean difference (MD) of efficacy and odds ratio (OR) of safety outcomes. Combination therapy of safinamide 50-100 mg/day and levodopa significantly reduced the mean total daily OFF time by 0.7 h (− 1.40 to − 0.02) compared to the combination therapy of rasagiline 1 mg/day and levodopa. Safinamide more effectively reduced UPDRS III (− 2.9, − 5.28 to − 0.52). Changes in PDQ-39 scores indicated a trend toward greater improvement in safinamide. There was no significant difference in safety outcomes. Compared to rasagiline, the combined therapy of safinamide and levodopa could significantly improve motor fluctuations for PD patients in China, without compromising safety.
Publisher
Nature Publishing Group UK,Nature Publishing Group,Nature Portfolio
Subject
/ Aged
/ Alanine - administration & dosage
/ Alanine - analogs & derivatives
/ Antiparkinson Agents - adverse effects
/ Antiparkinson Agents - therapeutic use
/ Benzylamines - administration & dosage
/ Benzylamines - adverse effects
/ Benzylamines - therapeutic use
/ China
/ Female
/ Humanities and Social Sciences
/ Humans
/ Indans - administration & dosage
/ Levodopa
/ Levodopa - administration & dosage
/ Male
/ Matching-adjusted indirect comparison
/ Monoamine oxidase type B inhibitors
/ Parkinson Disease - drug therapy
/ Safety
/ Science
